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Model-based study of the effects of the hemodialysis technique
on the compensatory response to hypovolemia.
Background. Hemodialysis technique (dialysate composi-
tion, filter, convection/diffusion ratio, etc.) can have an impact
on the patient’s tendency to acute hypotension. We have ex-
amined the hypothesis that the dialysis technique affects the
hypotension risk by altering the cardiovascular compensatory
response to hemodialysis-induced hypovolemia.
Methods. Twelve hypotension-prone subjects were studied
during six sessions of conventional bicarbonate dialysis (BD)
and six sessions of acetate-free biofiltration (AFB). Blood vol-
ume (BV) control system was used in AFB to provide a BV
change equivalent to the BV change observed in BD. The ef-
ficacy of reflex compensatory mechanisms was assessed by a
model-based computer analysis of the BD and AFB sessions.
Results. BD sessions were complicated by hypotension more
frequently than the AFB ones (34/66 BD vs. 18/66 AFB). Hy-
potension arose about 60 minutes earlier in BD (123 ± 41 min-
utes in BD vs. 183 ± 25 minutes in AFB, P < 0.01), and after a
smaller BV reduction (hypotension BV 7.9% ± 2.0% in BD vs.
10.9% ± 2.6% in AFB, P < 0.05). Model-based computer anal-
ysis of the sessions without hypotension revealed differences
in peripheral resistance adaptation (9% ± 9% BD vs. 19% ±
7% AFB, P < 0.05) as well as in the stroke volume reduction
(19% ± 8% BD vs. 10% ± 8% AFB, P < 0.001). Model anal-
ysis of sessions with hypotension indicated that compensatory
mechanisms were almost inoperative in BD, whereas a residual
capacity to control peripheral resistance and cardiac contractil-
ity was present in AFB. Model simulations demonstrated that
hypotension occurred later in AFB since the residual compen-
satory capacity in AFB was able to sustain the arterial pressure
for larger BV reductions (8.3% BD vs. 11.2% AFB).
Conclusion. The increased risk of acute hypotension in BD
compared to AFB is caused by a therapy-induced inhibition of
reflex compensatory response to hypovolemia.
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Acute hypotension is a common intratreatment com-
plication of chronic renal replacement therapies by
hemodialysis, with an incidence still reported to be
around the 20% to 30% of treatments [1, 2]. Apart from
patient discomfort, acute hypotension also leads to a less
effective treatment, especially in terms of body water re-
moval. Sessions complicated by hypotension often end
without achieving the correct dry body weight. In the
long run, repetitive hypotensive episodes yield a chronic
hydroelectrolytic derangement that promotes cardiovas-
cular side-effects, leading the patient to have chronically
unstable behavior.
Patient susceptibility to intradialytic hypotension ex-
hibits large intrasubject variability and several factors
have been ascribed to the pathogenesis of this compli-
cation. In subjects prone to acute hypotension, the first
determinant of the hypotensive event is the hemodialysis-
induced intravascular hypovolemia due to plasma-water
ultrafiltration [2–4]. To prevent excessive hypovolemic
stress, the online monitoring of circulatory blood volume
reduction is rapidly gaining acceptance in clinical practice
[5–7]. Actually, arterial pressure response is not simply
determined by the blood volume changes since it closely
depends on the short-term reflex capability to compen-
sate for hypovolemia [8]. Indeed, significant differences
between patients prone to hypotension can be noted also
when the blood volume reduction is similar. Also, isov-
olemic hemodialysis can result in hypotension [9].
Additional therapy-related factors may potentially
determine the patient’s susceptibility to hemodialysis.
Among these factors, the composition and quality of
dialysate, filter membrane biocompatibility, and the con-
vection/diffusion rate seem to influence the patient’s ten-
dency to acute hypotension. As a pertinent example, the
replacement of most of the acetate with bicarbonate in
standard hemodialysis has resulted in a decrease in intra-
dialytic hypotensive episodes [10–12]. The role of acetate
has been attributed to an acetate-induced impairment of
cardiovascular reactivity. In fact, acetate dialysis stimu-
lates nitric oxide synthesis [13] and endogenous nitric
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oxide overload has a significant neuromodulator activity
[14], with the net apparent effect of vagal activation and
sympathetic inhibition [15]. Autonomic compensatory re-
sponse plays a pivotal role in maintaining stable arterial
pressure during hemodialysis. Thus, the patient’s capac-
ity to compensate for hypovolemia could be worsened
by exposure to acetate as well as to other therapy-
dependent stimuli because of the inhibition of the short-
term autonomic-mediated reflex mechanisms controlling
cardiovascular functions.
In line with this hypothesis, the present study in-
vestigated the cardiovascular compensatory response
to hypovolemia, in a population of 12 end-stage renal
disease (ESRD) hypotension-prone patients, during a
widespread conventional therapy [bicarbonate dialysis
(BD)]. In order to show that the dialysis technique di-
rectly impacts on the risk of hypotension, the same pa-
tients were also studied during an alternative technique
[acetate-free biofiltration (AFB)], which has resulted in
a better hemodynamic outcome [16]. A blood volume
control system [17] was used in AFB to have blood vol-
ume changes similar to those observed in BD treatment.
The effectiveness of the compensatory response to hy-
povolemia was then studied by means of model-based
computer simulations of BD and AFB treatments.
METHODS
Subjects
Twelve patients with ESRD in renal replacement ther-
apy with three times a week 4-hour maintenance double-
needle hemodialysis at the dialysis center of the Infermi
Hospital (Rimini, Italy) were enrolled (N = 12, four
males and eight females; age 73.8 ± 8 years old, range
55 to 84 years; and weight 66 ± 11 kg, range 52.5 to
87.5 kg). All the participants provided informed consent
for participation in this study.
Etiologies of the renal failure in the participants were
nephrosclerosis (6), chronic glomerulonephritis (3), poly-
cystic kidney disease (2), and diabetic nephropathy (1).
No severe abnormalities were found upon physical ex-
amination. None of the patients had been treated with
vasoactive substances, had experienced an acute myocar-
dial infarction or chronic cardiac rhythm abnormalities
nor had they been treated for heart failure. All the pa-
tients had a good vascular access (blood flow rate greater
than 250 mL/min), an equilibrated Kt/V of at least 1.13,
and residual diuresis lower than 400 mL/day.
All patients were classified as hypotension-prone based
on recent incidence of hemodialysis-induced hypotension
(at least two of their most recent 12 treatments com-
plicated by acute hypotension). Intradialytic hypoten-
sion was defined as one of the following three situations:
(1) systolic blood pressure ≤90 mm Hg, accompanied
by symptoms and therapeutic maneuvers (saline or hy-
pernatric infusions, plasma expander, Trendelenburg or
other maneuvers, reduction in blood flow, stop of ultra-
filtration); (2) systolic blood pressure reduction ≥25 mm
Hg compared to the predialysis value, in the presence
of symptoms and therapeutic maneuvers; or (3) systolic
blood pressure ≤90 mm Hg, accompanied by a reduction
of at least 20 mm Hg from the predialysis value. Incidence
of hypotension was 2/12 in two subjects, 3/12 in one, 4/12
in two, 6/12 in two, 8/12 in two, 9/12 in one, and 10/12 in
two.
Experimental design and run-in
After a run-in period, all the patients underwent a
4-week study period. The study was developed according
to a prospective, crossover, parallel group design, with
two sequences. Six patients were treated first with BD
(2 weeks) and then by AFB (2 weeks) and six patients
were treated first with AFB (2 weeks) and then by BD
(2 weeks). One patient in the AFB-BD sequence
dropped out because of a persistent intratreatment atrial
fibrillation.
Each patient underwent an observational run-in period
on conventional bicarbonate dialysis (see BD treatment,
below) lasting 2 weeks. The run-in period was aimed at
correcting and optimizing the prescription of postdialysis
dry body weight and establishing the blood volume re-
duction to be set in the blood volume control system in
the AFB treatment.
Postdialysis body weight was determined on the basis
of both the traditional clinical parameters (skin and sub-
cutaneous hydration state, jugular vein, predialysis and
intradialytic blood pressure behavior, postdialysis stand-
ing blood pressure, and intratreatment symptoms, such as
muscular cramps) as well as the radiologic signs related
to the hydration status (cardiothoracic index, myocardial
diameters, pulmonary blood flow distribution, and vascu-
lar pedicle aspect).
After having established the optimal dry body weight
it was verified that postdialysis inferior vena cava diame-
ter (VCD) determined by echography and corrected for
body surface area was in the range of 10 to 14, which
indicated an adequate cardiac filling pressure.
The weight loss normalized blood volume reduction
(BV/WL) to be prescribed in the AFB treatment was
established as the average of the spontaneous blood vol-
ume reductions at the end of the run-in sessions without
hypotension, normalized with respect to the patient end-
treatment weight loss.
BD treatment
The BD treatment was a conventional bicarbonate
dialysis session [polysulphone (PS) membranes of 1.7 m2
PS-low flux] (Fresenius MC AG, Bad Homburg,
Germany). Dialysate flow rate was 500 mL/min and bath
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temperature was constant at 36.5◦C. Both the ultrafiltra-
tion rate and dialysate conductivity were kept constant
during the treatment. The duration of dialysis was be-
tween 210 and 270 minutes. The composition of dialysate
was sodium 140 mEql/L, potassium 2.5 mEq/L, bicarbon-
ate 34 mEql/L, acetate 3.0 mEq/L, chloride 109 mEq/L,
calcium 3.0 mEq/L, magnesium 1.0 mEq/L, and glucose
1.0 g/L. The percentage reduction of blood volume (%R-
BV) was measured continuously during the entire treat-
ment (HemoscanTM; Gambro-Dasco S.p.A., Medolla,
Italy).
AFB treatment
The AFB treatment was acetate-free biofiltration with
controlled blood volume. It consisted of a hemodiafil-
tration technique (polyacrylonitrile membrane AN69)
(Hospal S.p.A, Bologna, Italy) in which the dialysate
is buffer-free and acid-base correction is obtained by
postfilter infusion of a 145 mEq/L sodium bicarbon-
ate fluid [18]. The composition of dialysate was sodium
139 mEql/L, potassium 3.0 mEq/L, chloride 147.5 mEq/L,
calcium 4.0 mEq/L, magnesium 1.0 mEq/L, and glucose
1.0 g/L. In order to deliver a blood volume reduction dur-
ing the AFB treatment equivalent to the BD treatment a
blood volume control system (HemocontrolTM) (Hospal
S.p.A.) was employed. This automatic system continu-
ously controls the blood volume profile during the ses-
sion to obtain a goal blood volume reduction at the end
of the treatment that is the prescribed BV/WL ratio. This
is achieved by moment-to-moment adjustment of ultra-
filtration rate and dialysate conductivity by a feedback
control system using the deviation of measured %R-BV
from the prescribed blood volume profile as input sig-
nal [17]. Other factors such as treatment time, blood and
dialysate flow rates, and dialysate temperature were kept
with the same as for the BD treatment.
Measurements and data collection
During each session (66 BD + 66 AFB), the %R-BV
signal was acquired with a frequency of one sample per
minute.
Systolic and diastolic arterial blood pressures were
measured every 15 minutes by an automatic oscillomet-
ric sphygmomanometer (BP100) (Gambro AB, Lund,
Sweden). The occurrence of typical low blood pressure
symptoms (muscular cramps, headache, dizziness, vom-
iting, nausea, and sweating) and the times of any acute
hypotension episodes were also recorded.
Since the model-based computer analysis was limited
to the midweek dialyses only (two BD and two AFB
for each patient), a 12-lead ECG Holter (H-12 Holter)
(Mortara Instrument, Inc., Milwaukee, WI, USA) was
recorded during these sessions and an array containing
the beat-to-beat heart rate was extracted from the R-R
time series. %R-BV and heart rate time series, before be-
ing analyzed by the model, were low pass filtered with a
digital Butterworth filter to remove the high-frequency
variability.
Plasma Na+, K+, Ca2+, HCO3− concentrations, and pH
were also measured before and after the midweek treat-
ments (BG Electrolytes) (Instrumentation Laboratory,
Milan, Italy).
Qualitative description of the computer model
Cardiovascular response to hemodialysis-induced hy-
povolemia was simulated using the mathematical model
presented in previous works [8, 19] to which a few ad-
justments were made to analyze data from the present
study. An accurate description of the mathematical
model, including equations and parameter assignment,
can be found on the Internet Web site www-bio.deis.
unibo.it/DialSim.html. Here, only the main adjustments
and the relevant improvements are outlined.
The model of the circulatory system was in accor-
dance with the hydraulic equivalent already shown in [8].
Briefly, it includes (1) the systemic circulation comprised
of three compartments in series (arterial, microcircula-
tory and venous); and (2) the cardiac pump represented
by a single compartment (right atrium) and by the Star-
ling law, linking the right atrium pressure to the stroke
index.
The model of the short-term reflex compensation to hy-
povolemia was rearranged according to the block scheme
shown in Figure 1. As in the previous formulation of the
model, two distinct afferent pathways were considered:
one for the arterial [20] and the other for the cardiopul-
monary [21] sides. The model parameter, Kaff, allows the
assignment of a different relative weight to the two path-
ways. Previous model-based analyses [8, 19] showed that
in hypotension-prone patients Kaff typically ranges from
−0.1 to −0.5, indicating that the afferent pathways are
weighted toward the arterial side. Kaff was arbitrarily set
to −0.3 for the analysis of data of present study’s data.
Afferent pathways determine the efferent autonomic
tone, in which accordance with current physiologic
knowledge [22], drives the compensatory response to hy-
povolemia by way of four distinct mechanisms (see Fig. 1):
(1) the decrease in venous capacity that causes an en-
hancement in the venous return; (2) the increase in total
peripheral resistance that allows for the rise of arterial
pressure in proximal arteries; (3) the increase in car-
diac contractility; and (4) the increase in heart rate to
optimize the cardiac output. Four distinct gains express
the efficiency of the short-term reflex compensatory re-
sponse: Kv for venous capacity, Kr for total peripheral
resistance, Ksv for stroke volume, and Khr for heart rate.
Each of these parameters may range between 0 and 1.
When the parameter is equal to 0, the corresponding
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Fig. 1. Block diagram illustrating the model
used to simulate the short-term compensatory
mechanisms to hypovolemia. Variations of
arterial (Pa) and right atrial (Pra) pressures
compared with the values at the beginning of
treatment (Pae and Prae, respectively) excite
the efferent adrenergic tone (T), which ac-
tuates vasoconstriction of both venous (Vvu)
and microcirculatory (Rm) vessels, as well
as improving cardiac function through in-
otropic regulation of stroke volume (SV) and
chronotropic regulation of heart rate (HR).
Adrenergic stimulation modifies the condi-
tions of effectors relative to initial values
(Vvue, Rme, SVe, and HRe). The effectiveness
of each of these regulatory pathways was char-
acterized by a parameter (Kv, Kr, Ksv, and
Khr) that can range from 0 to 1 (0 = total in-
hibition and 1 = maximal efficiency).
regulatory mechanism is inoperative, whereas the mech-
anism is maximally effective when the parameter is equal
to 1.
In the previous model formulation, the measured heart
rate was considered as a model input directly control-
ling the heart activity. Conversely, in the model used for
the present analysis, the control of chronotropic and in-
otropic heart activity is operated through two negative
compensatory feedbacks (the bottom two pathways in
Fig. 1). This adjustment was introduced in order to have
the heart rate as a model output quantity to be compared
with the measured one.
A relevant improvement concerns the computation by
the model of both diastolic and systolic blood pressure,
since both these quantities were available as measured
data. A simple Windkessel equation [23], based on the to-
tal peripheral resistance and arterial compartment com-
pliance, was used to calculate the typical systolic rise and
diastolic drop in arterial pressure in the course of the car-
diac cycle by imposing the cardiac output computed by
the model. The maximum and minimum of this pressure
curve were considered as the systolic (Ps) and diastolic
(Pd) pressure, respectively. The mean arterial pressure,
derived according to the formula Pm = 2/3 ∗ Pd + 1/3
∗ Ps, was then used in the circulatory model as in the
previous implementation.
The identification process reflects all the modifications
made to the model structure. In regard to the previous
formulation, only the %R-BV was used as model input
while systolic and diastolic arterial pressure as well as
heart rate simulated by the model (i.e., the model out-
puts) were used in the identification process of the control
loop model parameters.
Data analysis by computer model
%R-BV data collected in each study session was im-
posed as time-varying input to the computer model and
model equations were numerically solved in order to
compute the simulated systolic and diastolic arterial pres-
sures as well as the simulated heart rate as a function of
dialysis time. In the case of sessions with hypotension,
simulation was limited to 15 minutes before the hypoten-
sion onset since following data could be confounded by
the therapeutic maneuvers employed (e.g., infusion, re-
duction in blood flow, cessation of ultrafiltration).
By using an iterative procedure, the optimal values of
the model parameters Kv, Kr, and Ksv were identified by
best-fitting simulated pressure and heart rate curves to
the measured data. The parameter Khr was not included
in the identification procedure and a fixed value was used
(Khr = 0.4). After parameter identification, the changes in
stroke volume, cardiac output, total peripheral resistance
and venous capacity occurring in each study session were
estimated. The accuracy of the model in predicting such
hemodynamic quantities has been examined in a previous
study [8].
Statistical analysis
The results are expressed using mean ± SD. For the
model parameters 25th and 75th percentiles are also re-
ported. Frequency of hypotension episodes and symp-
toms in the two dialysis techniques were compared
through paired t test. Collapse time and %R-BV in
the two techniques were compared through unpaired
two sample t test. Repeated measures analysis of vari-
ance (ANOVA) was used to perform a factorial analysis
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Fig. 2. Comparison of hypotensive episodes
and collapse. (A) Frequency of dialyses com-
plicated by hypotensive episodes [hypoten-
sion 51%±30% for bicarbonate dialysis (BD)
vs. 27% ± 30% for acetate-free biofiltration
(AFB)] and by at least one symptom (symp-
toms 18% ± 19% for BD vs. 7% ± 15% for
AFB). Frequencies were calculated for each
patient as the incidence of sessions with com-
plications over the six BD and six AFB ses-
sions, respectively; mean ± standard devia-
tion of these frequencies for the 11 patients
are shown. (B) Percentage reduction in blood
volume before the hypotension episode [col-
lapse percentage reduction of blood volume
(%R-BV) 7.9% ± 2.0%, N = 34 for BD vs.
10.9% ± 2.6%, N = 18 for AFB) and time of
hypotension (collapse time 123 ± 41 minutes
for BD vs. 183 ± 25 minutes for AFB).
Table 1. Incidence of sessions complicated by acute hypotension
during the 4 weeks of study
Hypotension Incidence
First 2 weeks Second 2 weeks
Sequence BD AFB AFB BD
BD-AFB 17/36 7/36
(57%) (23%)
AFB-BD 11/30 17/30
(31%) (47%)
Abbreviations are: BD, bicarbonate dialysis; AFB, acetate-free biofiltration.
and to test the dependence of each quantity on two in-
trasubject parameters: time during dialysis and dialysis
technique. Differences were considered as statistically
significant when the box-corrected probability level on
the within-subject F tests was less than 0.05. Arterial pres-
sure and heart rate predicted by the computer model were
compared with measured values, according to the Bland-
Altman method [24].
RESULTS
Hypotension
The incidence of sessions complicated by hypoten-
sive episodes was almost double in BD compared to
AFB (34/66 for BD vs. 18/66 for AFB). One patient had
more hypotensive episodes in AFB (4/6 for BD vs. 5/6
for AFB), while the other 10 subjects developed symp-
tomatic hypotension more frequently during BD treat-
ments (50% ± 29% for BD vs. 15% ± 19% for AFB).
Also sessions without acute hypotension, but with pa-
tient discomfort, were more frequent in BD than in AFB
(Fig. 2A). The larger incidence of hypotension in BD
treatment was observed independently of the order in
which the two treatments were delivered (Table 1).
Importantly, the critical blood volume reduction (i.e.,
the %R-BV at which collapse occurred) was lower in BD
than in the AFB (Fig. 2B). Similarly, hypotensive episodes
occurred around 60 minutes sooner in BD than in AFB
(Fig. 2B). No differences were noted in the total weight
loss between the two treatments (2.28 ± 0.61 kg for BD
vs. 2.24 ± 0.75 kg for AFB).
The hypotension outcome clearly indicated that the
BD treatment increases the risk of acute intradialytic
hypotension by reducing patient’s resistance to hypov-
olemia. To assess whether this phenomenon was due to
differences in the effectiveness of the compensatory re-
sponse to hypovolemia we used model-based computer
analysis.
Validation of computer model predictions
After model parameter identification, the arterial pres-
sure and heart rate predicted by the model were com-
pared with measured values (see Fig. 3). The comparison
evidenced a good correlation as confirmed by the high R
coefficient values for systolic pressure (0.93, P < 0.001),
for diastolic pressure (0.91, P < 0.001), and for heart rate
(0.89, P < 0.001). Of the differences in systolic pressure,
69.5% were within ±6.5 (±SD) mm Hg, 71.5% of the
differences in diastolic pressure were within ±6.4 (±SD)
mm Hg, and 60.5% of the differences in heart rate were
within ±4.5 (±SD) bpm. The mean error was determined
as 0.5% ± 3.7% for systolic pressure, 0.6% ± 4.4% for
diastolic pressure, and 1.6% ± 4.1% for heart rate. These
results confirmed the model’s reliability in predicting the
measured data.
Results of model analysis of the sessions not compli-
cated by hypotension are presented set apart from results
obtained in sessions with hypotension, in order to distin-
guish between the different dialysis outcomes.
Model-based analysis of hypotension-free sessions
Eight patients were included in this analysis: four pa-
tients with all the midweek sessions (two BD and two
AFB) hypotension-free and the other four patients for
whom only two sessions (one BD and one AFB) were
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Fig. 3. Bland-Altman scatter plot of differences between simulated
and measured heart rate (A), systolic pressure (B), and diastolic pres-
sure (C) for bicarbonate dialysis (BD) () and acetate-free biofiltration
(AFB) (+). Mean values ± standard deviations of the differences were:
0.01 ± 4.59 bpm for heart rate, 0.74 ± 6.46 mm Hg for systolic pressure,
and −0.05 ± 6.38 mm Hg for diastolic pressure.
hypotension-free. The remaining three patients were not
included since both the midweek BD sessions were com-
plicated by hypotension. Notably, these three patients
showed the highest hypotension frequency (5/6 in BD
treatment). Altogether, 12 BD and 12 AFB hypotension-
free sessions were considered.
According to the experimental design, the use of the
blood volume control system allowed the AFB treat-
ments to be delivered with blood volume reductions sim-
ilar to those observed in BD (Fig. 4). The electrolyte
plasma concentrations and pH also exhibited similar
changes (Table 2).
Systolic and diastolic pressures tend to remain sta-
ble throughout both treatments. A slightly lower systolic
pressure in the BD was observed (Table 3). Conversely,
a notable difference was evident in the heart rate, which
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Fig. 4. Percentage reduction in blood volume in 12 bicarbonate dial-
ysis (BD) () and in 12 acetate-free biofiltration (AFB) () sessions
without hypotension. No significant difference was found between the
two treatments (see Table 3).
Table 2. Electrolytes concentrations and pH in sessions without
hypotension [12 bicarbonate dialysis (BD) vs. 12 acetate-free
biofiltration (AFB)]
Sample Time
ANOVA
Chemical Treatment Pre Post Treatment
Na+ mEq/L BD 139.2 ± 1.9 138.7 ± 1.5 NS
AFB 138.8 ± 1.5 138.9 ± 2.1
Ca++ mEq/L BD 1.08 ± 0.14 1.13 ± 0.14 NS
AFB 1.13 ± 0.09 1.18 ± 0.18
K+ mEq/L BD 5.11 ± 0.53 3.94 ± 0.28 NS
AFB 5.09 ± 0.39 3.86 ± 0.31
HCO3− mEq/L BD 23.13 ± 2.03 27.74 ± 2.55 NS
AFB 23.56 ± 1.71 27.75 ± 2.31
pH BD 7.36 ± 0.03 7.46 ± 0.04 NS
AFB 7.37 ± 0.02 7.45 ± 0.03
Abbreviations are: ANOVA, analysis of variance; Pre, values measured
before haemodialysis; Post, values measured at the end of the hemodialysis; NS,
not significant.
rises significantly in BD, whereas it remains stable in the
AFB treatment (Table 3).
Analysis of model parameters in the hypotension-free
sessions (Table 4) revealed that cardiovascular reactiv-
ity was worse in the BD treatments than in the AFB
treatments. In fact, all the parameters were on average
lower in the BD therapy than in AFB. The difference was
especially significant in the parameter Kr related to the
control of microvascular resistance and in the parameter
Ksv expressing the efficacy of inotropic control of cardiac
contractility.
Differences in the effectiveness of compensation to hy-
povolemia were also evident: the increase in total periph-
eral resistance in AFB was twice that exhibited in BD;
whereas, the decrease in stroke volume was twice greater
in BD compared to AFB (Table 5).
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Table 3. Pressure, heart rate, and blood volume in sessions without hypotension [12 bicarbonate dialysis (BD) vs. 12 acetate-free biofiltration
(AFB)]
Treatment time minutes ANOVA
0 90 180 Time Treatment
Systolic pressure mm Hg BD 122.4 ± 14.1 114.5 ± 16.4 114.8 ± 18.4 NS P < 0.01
AFB 120.1 ± 12.4 123.4 ± 17.8 122.6 ± 12.1
Diastolic pressure mm Hg BD 72.1 ± 10.1 68.7 ± 10.5 69.7 ± 11.9 NS NS
AFB 66.4 ± 5.9 71.7 ± 8.9 72.9 ± 11.4
Heart rate bpm BD 69.7 ± 9.73 78.7 ± 9.7 83.3 ± 9.5 P < 0.05 P < 0.01
AFB 71.5 ± 9.8 71.8 ± 12.3 75.2 ± 11.1
Blood volume reduction % BD – 6.84 ± 1.71 8.95 ± 2.41 P < 0.01 NS
AFB – 7.41 ± 2.12 8.81 ± 3.05
ANOVA is analysis of variance and NS is not significant.
Table 4. Model parameter identification in sessions without
hypotension
BD (N = 12) AFB (N = 12) t test
Kv mean ± SD 0.35 ± 0.25 0.60 ± 0.23 NS
(25% to 75%) (0.10–0.41) (0.30–0.91)
Kr mean ± SD 0.24 ± 0.24 0.90 ± 0.15 P < 0.001
(25% to 75%) (0.10–0.42) (0.70–0.94)
Ksv mean ± SD 0.21 ± 0.3 0.73 ± 0.4 P < 0.01
(25% to 75%) (0.10–0.4) (0.30–0.92)
Abbreviations are: BD, bicarbonate dialysis; AFB, acetate-free biofiltration;
Kv, efficiency of venous capacity regulation (maximum efficiency Kv = 1); Kr,
efficiency of peripheral resistance regulation (maximum efficiency Kr = 1); Ksv,
efficiency of stroke volume regulation (maximum efficiency Ksv = 1); NS, not
significant.
Table 5. Percent changes of cardiac output (CO), total peripheral
resistance (TPR), stroke volume (SV), and venous capacity (VC) in
sessions without hypotension
BD (N = 12) AFB (N = 12) t test
CO % −2.1 ± 6.3 −3.1 ± 5.1 NS
SV % −19.1 ± 8.2 −10.7 ± 7.8 P < 0.01
TPR % 9.1 ± 9.4 18.9 ± 6.6 P < 0.05
VC % −14.7 ± 5.5 −14.8 ± 4.5 NS
Abbreviations are: BD, bicarbonate dialysis; AFB, acetate-free biofiltration;
CO, percent changes in cardiac output; TPR, percent changes in total
peripheral resistance; SV, percent changes in stroke volume; VC, percent
changes in venous capacity; NS, not significant.
The mean values of the Kv, Kr, and Ksv parameters
were considered to be representative of the compen-
satory response exhibited in the BD and AFB treat-
ments without hypotension. Using these two sets of mean
parameters (see Table 4) and the blood volume curves
shown in Figure 4 as model input, virtual BD and AFB
treatments were simulated. The systolic and diastolic ar-
terial pressures as well as the heart rate of the virtual
treatments were then compared with the corresponding
experimental data (see Fig. 5) to demonstrate that the
two sets of parameters characterize the mean response in
BD and AFB during hypotension-free sessions.
A comparison between the cardiovascular responses
predicted by the model for the virtual BD and AFB ses-
sions is shown in Figure 6. Cardiac output as well as ve-
nous pressure appear to follow the same trend in both
treatments. On the other hand, treatment differences are
clearly evident for peripheral resistance and stroke vol-
ume. The latter fell markedly in the BD treatment (−23%
at 180 minutes), whereas the reduction was moderate in
the AFB treatment (−10% at 180 minutes).
Model-based analysis of sessions with hypotension
Seven patients were included in the analysis of sessions
with hypotension: four patients with only one BD and one
AFB sessions complicated by hypotension and three pa-
tients experiencing hypotension in both the midweek BD
sessions. For this second group of patients, one had both
the AFB sessions complicated by hypotension, whereas
the other two patients had only one midweek AFB ses-
sion with hypotension. For these two patients, just one of
the two BD sessions was considered, in order to main-
tain a balanced data set. Thus, eight BD and eight AFB
sessions with hypotension were considered.
In both BD and AFB treatments, the parameter Kv
was close to zero (Table 6), suggesting that the adapta-
tion of venous capacity to hypovolemia was ineffective
in the sessions with hypotension. Both Kr and Ksv were
close to zero in the BD treatments, whereas these param-
eters were significantly higher in the AFB treatments (see
Table 6).
To compare the pressure response to hypovolemia in
two treatments, the mean values of the BD and AFB pa-
rameters (Table 6) were used to simulate BD and AFB
dialyses with a linearly decreasing blood volume that
resulted in a 15% reduction in the blood volume after
4 hours. The results of these simulations are shown in
Figure 7, where the systolic pressure is plotted as a func-
tion of the blood volume reduction. In BD, the complete
lack of effectiveness in compensation (Kv = 0.02, Kr =
0.05, Ksv = 0.05) causes the systolic pressure to fall swiftly
in response to hypovolemia. Under this condition, the hy-
potension threshold is reached at a blood volume reduc-
tion of about 8%. Notably, this value closely matches the
critical blood volume observed in the BD sessions with
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Fig. 5. Comparison of simulated and mea-
sured arterial pressure and heart rate (mean
± SD) in bicarbonate dialysis (BD) (A) and
acetate-free biofiltration (AFB) (B) sessions
without hypotension. Model simulated pres-
sure and heart rate (continuous lines) used the
percentage reduction of blood volume (%R-
BV) curves shown in Fig. 4. as input. For
the simulation, the mean values of parame-
ters identified in the hypotension-free sessions
(see Table 4) were assigned (BD Kv = 0.35,
Kr = 0.24, and Ksv = 0.21; AFB Kv = 0.60,
Kr = 0.90, Ksv = 0.73).
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Fig. 6. Percentage changes in total periph-
eral resistance (TPR) (A), cardiac output
(CO) (B), venous pressure (Pv) (C), and
stroke volume (SV) (D) simulated by the
model during bicarbonate dialysis (BD) and
acetate-free biofiltration (AFB) without hy-
potension. The percentage reduction of blood
volume (%R-BV) curves used as model in-
puts are shown in Fig. 4. Parameters are those
reported in Fig. 5. Peripheral resistance and
stroke volume exhibited notable differences.
hypotension (see Fig. 7). In the case of AFB treatment,
the residual control of vascular resistance and heart con-
tractility (Kv = 0.01, Kr = 0.49, Ksv = 0.50) maintains
a sustained pressure up to a 5% blood volume reduc-
tion. Beyond this value, pressure falls and the hypoten-
sive threshold is crossed at a blood volume reduction of
about 12%. This value also closely agrees with the critical
blood volume threshold observed in AFB with hypoten-
sion (see Fig. 7). Hypotension occurs about 60 minutes
earlier in BD than AFB (see Fig. 7) that is comparable to
the timing of hypotension observed in the experimental
results.
DISCUSSION
In this study we have examined the impact of the
technique used to deliver hemodialysis treatment on the
cardiovascular system, focusing on the risk of hypoten-
sion in hypotension-prone patients. For this purpose,
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Table 6. Model parameter identification in sessions with hypotension
BD (N = 8) AFB (N = 8) t test
Kv mean ± SD 0.02 ± 0.07 0.01 ± 0.03 NS
(25% to 75%) (0.00–0.07) (0.00–0.05)
Kr mean ± SD 0.05 ± 0.09 0.49 ± 0.16 P < 0.01
(25% to 75%) (0.00–0.07) (0.39–0.52)
Ksv mean ± SD 0.05 ± 0.09 0.50 ± 0.27 P < 0.01
(25% to 75%) (0.00–0.05) (0.44–0.53)
Abbreviations are: BD, bicarbonate dialysis; AFB, acetate-free biofiltration;
Kv, efficiency in the venous capacity regulation (maximum efficiency Kv = 1);
Kr, efficiency in the peripheral resistance regulation (maximum efficiency Kr =
1); Ksv, efficiency in stroke volume regulation (maximum efficiency Ksv = 1); NS,
not significant.
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Fig. 7. Percentage change of systolic pressure simulated by the model
during a treatment that produces a percentage blood volume reduction
of 15% after 4 hours. The parameter values used for the simulations are
the mean values identified in hypotensive sessions [bicarbonate dialysis
(BD) Kv = 0.02, Kr = 0.05, Ksv = 0.05; acetate-free biofiltration (AFB)
Kv = 0.01, Kr = 0.49, Ksv = 0.50]. The critical percentage reduction of
blood volume (%R-BV) for the occurrence of hypotensive episodes in
BD and AFB treatments are also shown (mean ± SD).
the hemodynamic response to conventional dialysis us-
ing a predominantly bicarbonate-based buffer with a
small amount of acetate (BD), the worldwide dominant
hemodialysis modality, was compared with the hemody-
namic response to AFB, a technique that uses a buffer-
free dialysate with continuous post-filter infusion of a
sterile bicarbonate solution [25]. BD was proposed to
improve the hemodynamic stability compared with ac-
etate dialysis [11, 26, 27]. However, this benefit has not
always been confirmed [28, 29] and the improvement of
dialysis morbidity with BD remains controversial. AFB
has been proposed as an alternative to acetate or bicar-
bonate hemodialysis that gives better cardiovascular sta-
bility [30, 31]. In a crossover study Zucchelli, Santoro,
and Spongano [16], showed that the percentage of ses-
sions with symptomatic side-effects was lower in AFB
than in BD and that hypotensive events decreased sig-
nificantly. Hypotension incidence as well as symptomatic
side-effects observed in the present study (see Fig. 2) at-
tested to such differences. With respect to previous stud-
ies, we assured each patient had a similar blood volume
reduction and dry body weight in both treatments. Thus,
we can exclude that different hypotensive risk associated
with BD and AFB was due to a different therapy-induced
hypovolemia or body weight loss.
A novel result was that the critical blood volume
threshold (i.e., the relative blood volume reduction at
which acute hypotension occurred) was significantly
lower in BD than in AFB (7.9% ± 2.0% BD vs. 10.9% ±
2.6% AFB). As a direct consequence, hypotensive events
also occurred earlier in BD, thus demonstrating a differ-
ent cardiovascular tolerance to blood volume withdrawal
between BD and AFB.
Differences between the two treatments were also ev-
ident when only the sessions uncomplicated by hypoten-
sion were considered. In hypotension-free BD sessions,
systolic pressure was lower at the end of treatment com-
pared to AFB sessions whereas heart rate was higher
(see Table 3). To our knowledge, previous comparisons of
hemodynamic response between different dialysis tech-
niques did not distinguish between sessions with and
without hypotension. Acute hypotension is associated
with large reactive hemodynamic changes. Therefore, we
considered it appropriate to study the actual impact of
therapy on the cardiovascular system in hypotension-
free sessions where confounding reactive factors did
not influence the hemodynamics. Since treatment dif-
ferences were evident also in hypotension-free sessions,
we advanced the hypothesis that BD systematically re-
duces the cardiovascular compensatory responsiveness
to hemodialysis-induced hypovolemia.
To explore this hypothesis we utilized a model-based
computer analysis successfully used in the past to study
the role of compensatory mechanisms on the pressure
response to hypovolemia [8]. The model-based approach
constituted a quantitative framework useful for giving a
coherent explanation of the experimental observations.
A significant model improvement was the computation of
both systolic and diastolic arterial pressure. Apart from
the advantage of having twice the number of points avail-
able for the identification procedure, the tuning of model
parameters improved since systolic and diastolic pressure
reflect different information. Systolic pressure depends
more on cardiac output which is determined by myocar-
dial contractility and heart frequency, whereas diastolic
pressure is mainly influenced by the total peripheral resis-
tance which depends on the smooth muscle tone of small
arteries and arterioles.
In the present investigation, model analysis was crucial
in providing an explanation of the different heart rate re-
sponse observed in BD compared with AFB (Table 3).
The presence of a small amount of acetate in the BD
dialysate may be significant. Vincent et al [32] observed
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a myocardial depression induced by acetate buffer with
a significant increase in the heart rate. However, a direct
tachycardic effect of acetate upon the sinus node can be
excluded since a decrease in the heart rate generally fol-
lows acetate administration in animals [33].
To test the hypothesis that the different heart rate re-
sponse reflected the difference in arterial pressure only
and was not due to a direct effect of the therapies upon
the sinus node, we assigned a fixed value to the model
parameter Khr. The good agreement between the heart
rate simulated by model and measured heart rate (see
Fig. 5) validated this assumption. Under this condition,
model-based analysis revealed the important findings
that peripheral resistance constriction as well as cardiac
inotropism were blunted in hypotension-free BD ses-
sions. As a direct consequence, in the BD treatment,
chronotropic activation raised the heart rate in order
to maintain adequate cardiac output in the presence of
blunted inotropic control. In AFB, on the other hand, va-
somotor and cardiac contractility compensation was able
to sustain pressure without activating the baroreflex in-
crease in heart rate. Therefore, the increased heart rate
during BD may be ascribed to a positive compensation
for a therapy-induced depression in the contractile force
of vascular smooth muscle and cardiac fibers.
Model-based analysis also revealed the ineffectiveness
of venous compensation in dialysis sessions complicated
by hypotension (Kv close to 0 in both BD and AFB
techniques). On the contrary, in the hypotension-free
sessions the venous capacity control was adequate in
assuring hypovolemia compensation (Kv = 0.35 ± 0.25
in BD and Kv = 0.60 ± 0.23 in AFB). The pivotal role of
venous capacity in the genesis of hypotension was con-
firmed by the inverse relationship between the Kv val-
ues and the tendency to intradialytic hypotension: the
three patients with the highest frequency of hypotension
(78% of BD treatments) had Kv = 0, whereas the three
patients with the lowest incidence of hypotension (less
than 30% of BD treatments) had the highest Kv values
(Kv > 0.4).
An equivalent discriminating role was not evident with
regard to peripheral resistance. In fact, in the sessions
complicated by hypotension the compensation of periph-
eral resistance and stroke volume was again operative in
AFB, whereas it was ineffective in BD (see Table 6). The
unique difference ascribable to peripheral resistance was
the time of acute hypotension (see Fig. 7), which was
about 60 minutes earlier in BD than in AFB. Previous
investigations [34, 35] pointed out the inability to distin-
guish patients with a stable or unstable pressure response
to dialysis on the basis of peripheral vascular resistance
alone. According to our observations, the effectiveness
of venous capacity adaptation may be the crucial element
for cardiovascular stability during hemodialysis-induced
hypovolemia.
Evidence of venous pooling or impaired venous tone
in hemodialysis-induced hypotension in the presence of
blood volume reduction has already been reported [8, 36].
Dialysis patients with diastolic dysfunction due to high
sensitivity to cardiac filling pressure particularly suffer
from impaired venous capacity control [37]. Venous tone
affects cardiac filling during blood volume withdrawal.
The more venous capacity is reduced, the less venous re-
turn is assured to the right heart and thus indirectly the
cardiac output drops. Furthermore, effective regulation
of arterial vascular resistance coupled with inadequate
control of venous capacitance may trigger a dangerous
positive feedback. Blood volume withdrawal induces an
uncompensated lowering of venous pressure with a con-
sequent reduction in cardiac output responsible for a
decrease in arterial pressure that stimulates peripheral
vasoconstriction, which by closing the unstable loop
causes a further decrease in venous pressure. This behav-
ior was evident in the simulation of AFB with hypoten-
sion, where in the initial phase of hypovolemia, thanks
to the increase in arterial peripheral vascular resistance,
a paradoxic increase in the arterial pressure was evident
(see Fig. 7). However, in the second phase, the blood
pressure dropped sharply even if the control of periph-
eral resistance was operative because of the absence of
venous capacity compensation.
Notably, the present study has demonstrated a therapy-
induced deficiency in vessel and cardiac contractility in
BD treatment. Since a primary autonomic dysfunction
can be excluded, the reduced cardiovascular responsive-
ness in the BD treatment can be associated to an apparent
inhibition of a- and b-adrenergic stimulation. However,
the heart rate increase in BD is indicative of adequate car-
diac sympathetic tone. Therefore, the blunted contraction
of vascular smooth muscle and cardiac fibers during BD
could reflect the inhibition of intracellular effectors for
the action of adrenergic receptor stimulation.
One possible explanation for the reduced responsive-
ness to adrenergic stimulus could be an enhanced pro-
duction of endogenous nitric oxide in BD compared to
AFB, since nitric oxide overload inhibits the contractile
responses to adrenergic stimulation by limiting the trans-
membrane calcium L-type current [38]. The hypothesis
that an enhanced production of nitric oxide causes the
inhibition of sympathetic activity in patients with acute
hypotensive episodes has already been advanced [39].
Beasley and Brenner [40] investigated the role of ni-
tric oxide in hemodialysis hypotension and proposed the
hypothesis that hypotension is mediated by inflamma-
tory cytokine-induced NO production in vascular smooth
muscle cells. Acetate-containing dialysate [41] or filter
membrane [42, 43] is likely to stimulate the production
of the cytokine activators of nitric oxide synthesis. AFB
has been shown to cause less monocyte activation and
cytokine release than BD [44]. Moreover, in vitro studies
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on the effects of dialysate solutions with and without ac-
etate on the nitric oxide synthase (NOS) activity found
that acetate-containing dialysate up-regulated nitric ox-
ide production in endothelial cells [13, 45]. Emerging
evidence indicates that the responsiveness of the en-
dothelium to hemodialysis therapy may play a key role
in hemodynamic instability due to endothelium-derived
nitric oxide and endothelin [46]. Hence, the hypothesis
could be advanced that BD treatment causes a deficient
cardiovascular responsiveness in hypotension-prone pa-
tients because of an enhanced stimulation of nitric oxide
production in vascular smooth muscle and cardiac fibers.
An alternative or complementary plausible cause for
the enhanced adrenergic responsiveness in AFB could
be associated with the post-filter infusion of bicarbon-
ate buffer and with the significant convective mass trans-
fer that results. Purely convective transport across the
dialysis membrane has long been known to promote bet-
ter cardiovascular stability [47]. Moreover, in AFB the
subject receives direct infusion of bicarbonate solution
that is at room temperature. Infusion of cold fluid could
have an impact on the cardiac and vascular reactivity
comparable to cooled conventional dialysate, which has
generally been associated with increased cardiovascular
stability [48]. Thus, the disparity in the cardiovascular re-
activity between conventional BD and AFB could be also
ascribed to differing thermal balance and/or differing va-
soactive middle molecule removal because of the differ-
ent levels of convection present in the two therapies.
CONCLUSION
In the hypotension-prone patient, conventional BD in-
creases the risk of hypotension compared to AFB since
it worsens the patient’s responsiveness to hypovolemia.
Model-based computer analysis has revealed a therapy-
specific worsening of cardiovascular compensatory re-
sponse to adrenergic stimulation during BD treatment.
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